Infectious Diseases News

ORLANDO, Fla.--(BUSINESS WIRE)--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions regarding potential collaboration in quantitative MRI and imaging biomarkers. As part of these discussions, Imaginostics and Siemens Healthineers intend to continue dialogue concerning potential technical and commercial pathways for Imaginostics’ envisioned ImagiView™ and ImagiSight™ offerings and their potential...

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma to Present 17 Scientific Abstracts at AAD 2026...

CRYSTAL LAKE, Ill,--(BUSINESS WIRE)--Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray...

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations. The announcement is being made in time for World TB Day to underscore the continued importance of improving TB detection and prevention glo...

AUSTIN, Texas--(BUSINESS WIRE)--More than 1,000 samples have been enrolled in the Pattern Bioscience clinical trial evaluating the Pattern Pneumonia ID/AST Panel and Pattern System...

FAIRFAX, Va.--(BUSINESS WIRE)--Ahead of spring, the National Pest Management Association (NPMA) warns that ants, termites, mosquitoes and ticks are already on the move....

PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment of severe, inherited, neurometabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has selected ECUR-506, the company’s investigational in vivo targeted gene insertion therapy for neonatal-onset ornithine transcarbamylase (OTC) deficiency, to participate in the Chemistry, Manufacturing, and Cont...

OXFORD, England & EDINBURGH, Scotland--(BUSINESS WIRE)--ProImmune Ltd, a global leader in immunological reagents and services, today announced a collaboration with the University of Edinburgh’s Roslin Institute to advance veterinary immunology research through development and validation of novel species-specific Ankyron® binders. Increased understanding of animal health through the application of ProImmune’s proprietary Ankyron binding technology will enable development of new strategies for pr...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2025. “Our recent decision to advance oral epetraborole into a Phase 2 study for polycythemia vera highlights the growing opportunity across AN2’s boron chemistry pipeline and...

BALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems (Real Time), the industry-leading, KLAS Rated, and HITRUST Certified post-acute analytics solution, announced today its participation in the American Association for Post-Acute Care Nursing (AAPACN) 2026 Conference, taking place March 17–20 in Orlando, FL. As nursing professionals convene to explore best practices and emerging clinical innovations, Real Time and North Shore Health will highlight how live, data-driven approaches help post-acu...